Results 51 to 60 of about 1,821,409 (281)
Turning genome-wide association study findings into opportunities for drug repositioning
Drug development is a very costly and lengthy process, while repositioned or repurposed drugs could be brought into clinical practice within a shorter time-frame and at a much reduced cost.
Alexandria Lau, Hon-Cheong So
doaj +1 more source
Drug repositioning and repurposing for Alzheimer disease [PDF]
Drug repositioning and repurposing can enhance traditional drug development efforts and could accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia and mild cognitive impairment. Transcriptional profiling offers a new and highly efficient approach to the identification of novel candidates for repositioning
Ballard, Clive +10 more
openaire +3 more sources
Epigenetic reprogramming of lineage switching in cancer
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source
Expanding the Computational Drug Repositioning Toolbox
Repositioning of previously approved drugs is a promising methodology because it lowers the cost and duration of the drug development pipeline and reduces the likelihood of unforeseen adverse events.
Brown, Adam Samuel
core +4 more sources
Drug repositioning based on heterogeneous networks and variational graph autoencoders
Predicting new therapeutic effects (drug repositioning) of existing drugs plays an important role in drug development. However, traditional wet experimental prediction methods are usually time-consuming and costly.
Song Lei, Xiujuan Lei, Lian Liu
doaj +1 more source
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low
Kouji Banno +7 more
doaj +1 more source
The processes of reform in Victoria’s alcohol and other drug sector, 2011-2014 [PDF]
This paper explores issues and concerns related to the 2014 alcohol and other drug sector recommissioning process in Victoria. Overview In mid-2014, the Victorian Alcohol and Drug Association approached the Drug Policy Modelling Program, at the ...
Drug Policy Modelling Program
core
MagmaFlow: A desktop platform for artificial intelligence‐driven expression analysis
MagmaFlow is a free, no‐code platform for gene expression analysis. It generates interactive volcano plots, links genes to literature, pathways, and diseases, prioritizes candidates using millions of publications, identifies affected biological processes, builds network diagrams, and exports publication‐ready figures and reports for macOS and Windows ...
Carlos E. Buss +7 more
wiley +1 more source
DrugMechDB: A Curated Database of Drug Mechanisms
Computational drug repositioning methods have emerged as an attractive and effective solution to find new candidates for existing therapies, reducing the time and cost of drug development.
Adriana Carolina Gonzalez-Cavazos +8 more
doaj +1 more source

